peptides for FAQ

For growth hormone secretagogues with 24-hour half-lives like MK 677, missing three doses means plasma levels drop below therapeutic threshold. Resume dosing immediately at the standard dose. Do not double-dose to 'catch up.' The GH pulse amplification effect resets within 48 hours of resuming consistent administration. For shorter half-life peptides like CJC-1295/Ipamorelin, missing three doses has minimal impact on overall cycle effectiveness as long as the total cycle duration (8–12 weeks) is maintained.

Skip the 14-day metallothionein priming phase and you mobilise metals from tissue storage without adequate intracellular binding proteins to sequester them safely. Research from the Journal of Trace Elements shows that chelation initiated without MT upregulation increases plasma mercury by 40–60% transiently as metals redistribute from liver and bone to circulation. And a portion crosses the blood-brain barrier before renal excretion occurs. The correct sequence: zinc-methionine 30–50mg daily for two weeks, verify plasma zinc is 80–120 mcg/dL, then introduce chelation while continuing zinc. Chelation without priming is redistribution, not detoxification.

Administer peptides only after initial hematoma formation stabilises. Typically 48–72 hours post-injury. The acute inflammatory phase requires controlled cytokine expression (IL-1β, TNF-α, IL-6) to initiate the repair cascade, and premature anti-inflammatory intervention can delay osteoblast recruitment. BPC-157 has shown pro-angiogenic effects without suppressing early inflammation, making it theoretically safer during this window than NSAIDs, which directly inhibit COX enzymes critical to prostaglandin-mediated bone healing. TB-500's anti-inflammatory properties suggest delaying administration until week 2, when excessive inflammation becomes counterproductive.

Reduce injection volume and frequency. Irritation often results from injecting more than 0.5 mL subcutaneously in one site or hitting the same injection location repeatedly within 48 hours. Rotate injection sites by at least 2 inches between doses, staying within the general injury proximity (2–3 inches from the affected ligament). If redness persists beyond 24 hours or is accompanied by warmth and swelling, discontinue use and evaluate for allergic reaction or contamination. Persistent irritation can also indicate incorrect reconstitution concentration. Verify you're using the intended bacteriostatic water volume (typically 2–3 mL per vial). Never inject directly into inflamed tissue; target healthy subcutaneous fat adjacent to the injury zone.

Testosterone optimises DHT signalling to androgen receptors, but it doesn't directly raise IGF-1 in dermal tissue the way GH-releasing peptides do. Men on TRT with adequate DHT conversion but suboptimal GH secretion may still see density improvements from adding CJC-1295/Ipamorelin or MK-677. The pathways are complementary, not redundant.

Do not inject directly into the tendon itself. Tendon tissue has minimal vascularity and injecting into dense collagen fibers risks mechanical damage or localized hematoma. Inject subcutaneously 2–3 centimeters proximal or distal to the lateral epicondyle. The peptide circulates locally and reaches the injury site through capillary diffusion without requiring intra-tendon placement.

Metabolic adaptation is the likely cause. Your body downregulates NEAT (non-exercise activity thermogenesis) by 200–400 calories/day and reduces thyroid hormone conversion (T4 to T3) in response to sustained deficit. Solutions: implement a 10–14 day maintenance phase at estimated TDEE to restore leptin and thyroid function, then resume deficit. Alternatively, add Lipo-C (methionine, inositol, choline) to support hepatic fat metabolism and methylation pathways that regulate energy expenditure.

Peptide mechanisms target underlying tissue pathology, not acute symptom relief. Research models showing efficacy measure collagen organization, tensile strength, and adhesion density. Outcomes that manifest over weeks to months, not days. If you're evaluating based on immediate pain reduction, you're measuring the wrong endpoint. Structural tissue changes documented in animal models appear at 4–8 week timepoints, suggesting human timelines of 8–16 weeks for measurable capsular mobility improvements based on metabolic scaling.

Start them anyway, but adjust expectations. The inflammatory and early proliferative phases (weeks 0–6) are when peptides exert maximum effect because collagen synthesis rates are highest and cellular signaling is most active. By month three, the graft has entered the remodeling phase. Collagen is being reorganized under mechanical load rather than deposited de novo. BPC-157 and TB-500 still support tissue quality during this phase, but the timeline compression seen in early intervention studies (4–6 weeks faster recovery) drops to 1–2 weeks when started late. IGF-1 LR3 remains valuable for muscle recovery regardless of surgical timeline, as satellite cell activation continues throughout rehab.

Reassess storage and reconstitution first. If the lyophilised powder was stored above −20°C or the reconstituted solution above 8°C at any point, the peptide is likely inactive. Assuming proper handling, lack of response after 4 weeks suggests one of two scenarios: either the peptide doesn't work for your specific pathology (not all nerve damage responds to growth factor signaling), or the dosage is subtherapeutic. Animal models use 10–15mcg/kg body weight. For a 70kg person, that translates to 700–1050mcg daily, well above the common 250–500mcg range.

Striae albae (white stretch marks) represent mature scar tissue where initial inflammation has resolved, leaving a permanent dermal deficit with reduced vascularity and collagen density. Peptides still stimulate collagen synthesis in mature stretch marks, but improvement is slower and less dramatic than in striae rubrae (red stretch marks), which retain active inflammation and higher fibroblast activity. Clinical data shows 15–25% improvement in striae albae appearance over 16–20 weeks with consistent peptide use. Meaningful but not complete resolution. Microneedling combined with peptide application produces better outcomes for mature stretch marks by physically disrupting scar tissue and creating fresh wound healing response.

Administer BPC-157 at 500mcg twice daily, injected subcutaneously near the medial elbow. Pair with TB-500 at 2.5mg twice in the first week to reduce inflammation and promote tissue migration to the injury site. This won't fully repair a Grade II tear in two weeks—that requires 6–8 weeks under normal circumstances—but it accelerates the initial inflammatory phase and early collagen deposition enough that pain and grip strength may improve sufficiently for competition. You're managing damage, not reversing it. Post-fight, continue both peptides for another 4–6 weeks to complete structural repair.

Separate administration by at least 4–6 hours if using peptides with overlapping receptor pathways. Simultaneous dosing can create competitive binding that reduces effective concentration of both compounds. For example, BPC-157 and TB-500 both influence growth factor signaling, so staggered dosing (morning and evening) produces more consistent tissue responses than combined injections. Document exact timing and dose sequences in your methods section. Reviewers will ask.

Age reduces endogenous GHK-Cu concentrations by 60% between ages 20 and 60, and fibroblast proliferation rates decline by approximately 40% per decade after age 30. Exogenous peptide administration can partially compensate—BPC-157 and TB-500 mechanisms don't depend on baseline hormone levels, so their angiogenic and actin-regulating effects remain intact regardless of age. GHK-Cu becomes more important with age because declining endogenous levels mean less baseline collagen remodeling capacity. Older individuals may require longer peptide cycles (8–12 weeks vs 4–6 weeks) and higher GHK-Cu doses (2–3 mg vs 1–2 mg) to achieve comparable structural outcomes, but the mechanisms themselves remain functional.

Combining BPC-157 and TB-500 is common in musculoskeletal injury models because their mechanisms are complementary. BPC-157 addresses vascular supply while TB-500 handles structural repair. However, peptides with overlapping pathways (e.g., two angiogenic compounds) may not produce additive effects. KPV can be stacked with either BPC-157 or TB-500 if inflammation is the primary driver. Document all combinations in research logs. Peptide interactions are under-researched and confounding variables must be tracked.

Administer the first dose within 6–12 hours post-race if your goal is reducing acute inflammation and accelerating the initial repair phase. BPC-157 and GHK-Cu work through pathways that are most active during the first 48–72 hours when inflammation peaks and growth factor expression is elevated. Waiting a week means you've already passed through the acute phase where these peptides have the strongest effect. You'll still see benefits for lingering tendon issues, but the window for preventing delayed soreness closes fast.

Combining exogenous hCG with kisspeptin offers no synergistic benefit and risks over-stimulating Leydig cells, leading to aromatase upregulation and elevated estradiol that suppresses spermatogenesis. hCG directly replaces LH. Adding kisspeptin (which stimulates endogenous LH release) creates redundant signaling. Transition off hCG entirely before starting kisspeptin, allowing 2–3 weeks washout for exogenous LH activity to clear. The goal with kisspeptin is restoring physiological pulsatile LH, which exogenous hCG's steady-state pharmacokinetics disrupt.

Taper GLP-1 agonists over 4–6 weeks to minimize ghrelin rebound and appetite surge. Clinical evidence shows most patients regain two-thirds of lost weight within one year of abrupt cessation because the medication corrects impaired satiety signaling that returns when removed. Growth hormone secretagogues can be stopped without taper, though IGF-1 levels return to baseline within 2–3 weeks. Transition planning: increase protein to 2.5g/kg, maintain training volume, and monitor body composition monthly.

Take the peptide 24–48 hours before departure, not after landing. Circadian disruption begins the moment you board a flight crossing more than two time zones. Cortisol mistiming, melatonin suppression, and cytokine elevation start during the flight itself. Pre-loading Thymalin or Cartalax before travel allows immune and mitochondrial support to be active when circadian stress peaks. Waiting until you land means you're treating damage that's already accumulated.

NAC at doses above 1200mg/day causes nausea, bloating, or diarrhoea in 15–25% of users because unabsorbed NAC in the colon is metabolised by gut bacteria into hydrogen sulfide. Start at 600mg once daily with food for one week, then increase to 600mg twice daily. If GI symptoms persist, switch to sustained-release NAC formulations or split the dose into 400mg three times daily. Liposomal glutathione is an alternative, though less effective. It bypasses intestinal hydrolysis but delivers lower intracellular concentrations than NAC-driven synthesis.